Nampt/PBEF/Visfatin Upregulation in Colorectal Tumors, Mirrored in Normal Tissue and Whole Blood of Colorectal Cancer Patients, Is Associated with Metastasis, Hypoxia, IL1β, and Anemia
Table 2
Relationship between Nampt/PBEF/visfatin expression in whole blood and clinicopathological features of CRC.
Parameter
Nampt/PBEF/visfatin
value
Sex distribution, F/M ratio
36
CRC patients: 8/28
0.367
54
Controls: 18/36
Age, median (range)
CRC patients: 62 (33–92)
<0.001
Controls: 36.5 (18–78)
Disease stage:
0.126
I
3
0.482 (0.11–2.06)
II
11
0.824 (0.54–1.26)
III
18
0.852 (0.65–1.12)
IV
3
1.505 (0.75–3.06)
Not determined
1
1.108
Local advancement (T):
0.090
T2
4
0.495 (0.23–1.06)
T3
13
0.809 (0.55–1.19)
T4
19
0.984 (0.77–1.25)
Lymph node metastases (N):
0.232
N0
15
0.713 (0.52–0.98)
N1
13
0.915 (0.64–1.31)
N2
8
1.076 (0.69–1.67)
Distant metastases (M):
0.073
M0
32
0.798 (0.65–0.98)
M1
3
1.505 (0.75–3.03)
M
1
1.108
Anemia:
0.069
Nonanemic
21
0.732 (0.56–0.96)
Mild/moderate anemia
15
1.045 (0.80–1.37)
Data presented as means with 95% CI of normalized (against geometric mean of SDHA and TBP expression) relative (referred to as mean expression across sample set investigated) quantities of Nampt/PBEF/visfatin, calculated by qBasePLUS software.
